SC
OCUL icon

SMA Capital’s Ocular Therapeutix OCUL Stock Holding History

SMA Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Buy
1,098
+525
+92% +$4.76K ﹤0.01% 102
2026
Q1 		$4.85K Buy
+573
New +$5.46K ﹤0.01% 91

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SMA Capital's OCUL Position: Q2 2026 in Review

SMA Capital increased its Ocular Therapeutix (OCUL) stake by 92% in Q2 2026, buying an estimated $4.76K and bringing the position to 1,098 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #102.

SMA Capital first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • SMA Capital held 1,098 shares of Ocular Therapeutix worth $10.8K as of Q2 2026.
  • SMA Capital bought 525 Ocular Therapeutix shares in Q2 2026, an estimated $4.76K.
  • Ocular Therapeutix made up ﹤0.01% of SMA Capital's portfolio in Q2 2026, its #102 holding.
  • SMA Capital first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.